The impact of waist-to-hip ratio on clinical outcomes in metastatic breast cancer patients treated with aromatase inhibitors
The impact of waist-to-hip ratio on clinical outcomes in metastatic breast cancer patients treated with aromatase inhibitors
复制标题
DOI：
10.1016/j.breast.2008.01.007
复制
发表时间：
2008-08-01
期刊：
影响因子：
3.9
通讯作者：
Samur, Mustafa
中科院分区：
文献类型：
--
作者：
Artac, Mehmet;Bozcuk, Hakan;Samur, Mustafa
我们的目的是确定腹部脂肪分布是否会影响转移性乳腺癌（MBC）患者接受芳香化酶抑制剂（AI）治疗的结果。本研究共入组了42例接受一线激素治疗的MBC患者。单变量分析中与总生存率相关的因素是年龄。e-erb-B2表达强度（+++与其他免疫组化）和WHR，而只有WHR在多变量分析中保持显著性。中位总生存期为472天，而WHR = 0.92的患者未达到中位总生存< 0.92 and >期（对数秩统计= 9.76，P = 0.002）。同样，WHR = 0.92的患者的相应无进展生存期数据< 0.92 and >为423天与1004天（对数秩统计= 6.37，P = 0.012）。这项研究表明，腰臀比可能作为一个潜在的预测指标，MBC患者接受AI治疗。(c)2008爱思唯尔有限公司保留所有权利。
We aimed to identify whether abdominal fat distribution could affect the outcome in metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs) or not. A total of 42 MBC patients treated with first line hormonal therapy were enrolled in this study. Factors associated with overall survival in the univariate analysis were age. e-erb-B2 expression intensity (+++ versus others by immunohistochemistry), and WHR, whereas only WHR retained significance in the multivariate analysis. Median overall survival figures were 472 days versus unreached for patients with a WHR of < 0.92 and >= 0.92 (Log rank statistic = 9.76, P = 0.002). Similarly, the corresponding progression free survival figures for patients with a WHR of < 0.92 and >= 0.92 were 423 versus 1004 days (Log rank statistics = 6.37, P = 0.012). This study suggests that WHR may serve as a potential predictive marker in MBC patients treated with AIs. (c) 2008 Elsevier Ltd. All rights reserved.